Vence Luis, Palucka A Karolina, Fay Joseph W, Ito Tomoki, Liu Yong-Jun, Banchereau Jacques, Ueno Hideki
Baylor Institute for Immunology Research and Baylor Research Institute, Baylor University, Dallas, TX 75204, USA.
Proc Natl Acad Sci U S A. 2007 Dec 26;104(52):20884-9. doi: 10.1073/pnas.0710557105. Epub 2007 Dec 18.
Although it is accepted that regulatory T cells (T regs) contribute to cancer progression, most studies in the field consider nonantigen-specific suppression. Here, we show the presence of tumor antigen-specific CD4(+) T regs in the blood of patients with metastatic melanoma. These CD4(+) T regs recognize a broad range of tumor antigens, including gp100 and TRP1 (melanoma tissue differentiation antigens), NY-ESO-1 (cancer/testis antigen) and survivin (inhibitor of apoptosis protein (IAP) family antigen). These tumor antigen-specific T regs proliferate in peripheral blood mononuclear cells (PBMC) cultures in response to specific 15-mer peptides, produce preferentially IL-10 and express high levels of FoxP3. They suppress autologous CD4(+)CD25(-) T cell responses in a cell contact-dependent manner and thus share properties of both naturally occurring regulatory T cells and type 1 regulatory T cells. Such tumor antigen-specific T regs were not detected in healthy individuals. These tumor antigen-specific T regs might thus represent another target for immunotherapy of metastatic melanoma.
尽管人们公认调节性T细胞(Tregs)会促进癌症进展,但该领域的大多数研究考虑的是非抗原特异性抑制作用。在此,我们证明转移性黑色素瘤患者血液中存在肿瘤抗原特异性CD4(+) Tregs。这些CD4(+) Tregs可识别多种肿瘤抗原,包括gp100和TRP1(黑色素瘤组织分化抗原)、NY-ESO-1(癌胚抗原)和生存素(凋亡抑制蛋白(IAP)家族抗原)。这些肿瘤抗原特异性Tregs在体外培养的外周血单个核细胞(PBMC)中,针对特定的15肽发生增殖,优先产生白细胞介素-10(IL-10)并高表达叉头框蛋白3(FoxP3)。它们以细胞接触依赖的方式抑制自体CD4(+)CD25(-) T细胞反应,因此兼具天然调节性T细胞和1型调节性T细胞的特性。健康个体中未检测到此类肿瘤抗原特异性Tregs。因此,这些肿瘤抗原特异性Tregs可能是转移性黑色素瘤免疫治疗的另一个靶点。